畏光在干眼、偏头痛与创伤性脑损伤中的共同病理生理机制
本文通过PubMed文献综述探讨畏光在干眼病、偏头痛和创伤性脑损伤中的共同病理生理机制。三种疾病常共病并共享畏光症状,涉及外周和中枢神经系统失调及CGRP活性增强。现有治疗包括滤光眼镜、肉毒素和CGRP抑制,但许多患者畏光持续存在,需开发新疗法。
要点
- 干眼、偏头痛和TBI常共病并共享畏光症状,提示三叉丘脑通路共同机制。
- CGRP神经肽活性增强与畏光密切相关,介导中枢神经可塑性和超敏反应。
- 针对神经通路的治疗(如口服神经调节剂、经皮神经刺激)可考虑用于持续性畏光患者。
核心结论
- 干眼、偏头痛和TBI中的畏光提示共享三叉丘脑病理生理机制,由CGRP介导的中枢神经可塑性和超敏反应解释。
研究设计与样本
- 通过PubMed检索英文文献进行综述,聚焦畏光在干眼、偏头痛和TBI中的共享病理生理机制。
主要发现
- 干眼、偏头痛和TBI在一般人群中常见、常共病,并共享畏光症状。
- 在多种动物模型和人类中,外周和中枢神经系统成分的神经失调与畏光相关。
- CGRP活性增强与畏光密切相关。
- 当前畏光治疗包括屏蔽特定波长的眼镜、肉毒素和抑制CGRP及其受体,但许多患者畏光持续存在。
关键数值与推荐
- 当前畏光治疗包括屏蔽特定波长的眼镜、肉毒素和抑制CGRP及其受体。
- 许多患者尽管使用这些治疗仍持续畏光,需要开发新疗法。
- 针对神经通路的治疗策略(口服神经调节剂、经皮神经刺激)应考虑用于持续性畏光患者,尤其是传统治疗未控制症状的干眼患者。
临床怎么用
- 对干眼、偏头痛和TBI患者应评估畏光症状,认识其共享机制。
- 对传统治疗未控制症状的干眼患者,可考虑针对神经通路的治疗如口服神经调节剂或经皮神经刺激。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Photophobia is a potentially debilitating symptom often found in dry eye disease (DE), migraine and traumatic brain injury (TBI). METHODS: We conducted a review of the literature via a PubMed search of English language articles with a focus on how photophobia may relate to a shared pathophysiology across DE, migraine and TBI. RESULTS: DE, migraine and TBI are common conditions in the general population, are often comorbid, and share photophobia as a symptom. Across the three conditions, neural dysregulation of peripheral and central nervous system components is implicated in photophobia in various animal models and in humans. Enhanced activity of the neuropeptide calcitonin gene-related peptide (CGRP) is closely linked to photophobia. Current therapies for photophobia include glasses which shield the eyes from specific wavelengths, botulinum toxin, and inhibition of CGRP and its receptor. Many individuals have persistent photophobia despite the use of these therapies, and thus, development of new therapies is needed. CONCLUSIONS: The presence of photophobia in DE, migraine and TBI suggests shared trigeminothalamic pathophysiologic mechanisms, as explained by central neuroplasticity and hypersensitivity mediated by neuropeptide CGRP. Treatment strategies which target neural pathways (ie, oral neuromodulators, transcutaneous nerve stimulation) should be considered in patients with persistent photophobia, specifically in individuals with DE whose symptoms are not controlled with traditional therapies.
引用
- Diel RJ, Mehra D, Kardon R, et al. Photophobia: shared pathophysiology underlying dry eye disease, migraine and traumatic brain injury leading to central neuroplasticity of the trigeminothalamic pathway. Br J Ophthalmol. 2020. PMID: 32703784. doi:10.1136/bjophthalmol-2020-316417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。